Why the study?
Optimal management of patients with D5PSS-4/5 following R-da-EPOCH has not been adequately studied, as recommendations to avoid radiotherapy were based on limited data.
What is the clinical significance of end-of-treatment PET/CT imaging after R-da-EPOCH in patients with primary mediastinal large B-cell lymphoma?
Population
145 patients with PMLBCL treated with R-da-EPOCH across Greece
Comparison
Consolidative radiotherapy vs omission across PET/CT response categories
Design
Multicenter retrospective cohort study
Follow-up
Median 29.8 months
Authors
Loading...
End-of-treatment PET/CT may stratify risk after R-da-EPOCH in PMLBCL; leaves open prospective validation before guiding therapy.
What is the clinical significance of end-of-treatment PET/CT imaging after R-da-EPOCH in patients with primary mediastinal large B-cell lymphoma?
End-of-treatment PET/CT effectively stratifies risk in PMLBCL patients treated with R-da-EPOCH, with D5PSS 1-3 indicating excellent outcomes without radiotherapy, while D5PSS 5 indicates poor prognosis.
Vassilakopoulos et al. (2023) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: